
From September 2008 to January 2015, David Solomon was CEO of Zealand Pharma where he was responsible for taking the company public in 2011 as the latest life science company to list on the Copenhagen Stock Exchange.
Since then, he has been in a Norwegian biotech company and founded the life science investment fund Sund Capital. A little more than a month ago he took the reins in a US-based biotech company. Here, he hopes and believes that he can replicate the success he experienced during his six years in Zealand Pharma.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app